Comprehensive Genomic Profiling: Uncovering the Genetic Blueprint

Genomic profiling lies at the heart of personalized oncology care. Our comprehensive genomic tests analyze the genetic makeup of tumors, identifying specific mutations, alterations, and biomarkers that drive cancer growth. By unraveling the genetic blueprint of each patient’s tumor, we provide invaluable insights to guide targeted therapies and clinical decision-making.

Liquid Biopsy: A Non-Invasive Window to Cancer

Our liquid biopsy tests offer a non-invasive alternative to traditional tissue biopsies. By analyzing circulating tumor DNA (ctDNA) or other biomarkers present in blood samples, we can detect and monitor genetic mutations, treatment response, and disease progression. Liquid biopsies provide a dynamic and real-time view of the tumor’s genetic profile, enabling healthcare providers to adapt treatment plans as needed.

HER2 Testing: Optimizing Breast Cancer Treatment

Accurate HER2 testing is crucial for guiding treatment decisions in breast cancer. Our HER2 testing services utilize cutting-edge technology to determine HER2 gene amplification or overexpression, enabling precise targeting of therapies such as HER2-targeted monoclonal antibodies. Accurate HER2 status determination ensures that patients receive the most effective and personalized treatment for their specific breast cancer subtype.

Lung Cancer Genomic Profiling: Empowering Precision Therapies

Lung cancer genomic profiling is essential for identifying specific genetic mutations and alterations that drive the disease. Our advanced tests analyze tumor tissue or liquid biopsy samples to uncover actionable genetic alterations, such as EGFR, ALK, ROS1, or BRAF mutations. This information guides the selection of targeted therapies, immunotherapies, and clinical trial enrollment, empowering patients with personalized treatment options.

Immune Profiling: Harnessing the Power of the Immune System

Immunotherapy has revolutionized cancer treatment. Our immune profiling tests evaluate the tumor microenvironment, immune cell populations, and expression of immune-related biomarkers. By understanding the immune landscape, we can predict patient response to immunotherapies and identify potential combination therapies to enhance treatment efficacy.

Minimal Residual Disease (MRD) Monitoring: Tracking Treatment Response

MRD monitoring involves the detection of residual cancer cells that may remain after treatment. Our sensitive MRD testing methods detect minimal amounts of cancer cells in blood or bone marrow samples, providing valuable information about treatment response, disease recurrence, and long-term prognosis. MRD monitoring plays a crucial role in guiding post-treatment surveillance and optimizing patient outcomes.